Value-based insurance design and antidiabetic medication adherence

American Journal of Pharmacy Benefits

Volumn 2, Issue 1, 2010, Pages 39-44

  Chang, Andrew ^a   Liberman, Joshua N ^b   Coulen, Charmaine ^b   Berger, Jan E ^b   Brennan, Troyen A ^c  

^a CVS Caremark   (United States)

^b Health Intelligence Partners ^*

^c Health Intelligence Partners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; GLITAZONE DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; RETROSPECTIVE STUDY;

EID: 77953432178     PISSN: 19454481     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
2. Kaiser Family Foundation, Health Research & Educational Trust. Employer Health Benefits 2008 Annual Survey. http://ehbs.kff.org/pdf/7790.pdf. Accessed December 9, 2008.
3. Klepser DG, Huether JR, Handke LJ, Williams CE. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. J Manag Care Pharm. 2007;13(9):765-777.
4. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
5. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
6. Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry. 2005;42(3):293-310.
7. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9):509-517.
8. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-645.
9. Nicholson S. The effect of cost sharing on employees with diabetes. Am J Manag Care. 2006;12(spec no):SP20-SP26.
10. Bierman AS, Bell CM. Penny-wise, pound-foolish: the costs of cost-related medication restriction. Med Care. 2004;42(7): 623-625.
11. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26(2):w195-w203.
12. Fendrick AM, Chernew ME. Value-based insurance design: a "clinically sensitive" approach to preserve quality of care and contain costs. Am J Manag Care. 2006;12(1):18-20.
13. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: Centers for Disease Control and Prevention; 2008. www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed November 5, 2009.
14. Centers for Disease Control and Prevention (CDC). State-specific incidence of diabetes among adults - participating states, 1995-1997 and 2005-2007. MMWR Morb Mortal Wkly Rep. 2008;57(43):1169-1173.
15. National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics, 2007. Bethesda, MD: National Institutes of Health; 2008. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/. Accessed November 5, 2009.
16. Bell DS. Current status of diabetes treatment. South Med J. 2002;95(1):24-29.
17. Kue Young T. Mustard C.A. Undiagnosed diabetes: Does it matter? Canadian Medical Association Journal 2001 164 1 24-28 17. Young TK, Mustard C. Undiagnosed diabetes: does it matter? CMAJ. 2001;16(1):24-28. (Pubitemid 32094880)
18. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 suppl):S170-S176.
19. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. Am J Manag Care. 2007;13(6 pt 2):370-376.
20. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-112.
21. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200-209.